Abdel-Aziz Mahmoud I, Ali Mostafa A Sayed, Hassan Ayman K M, Elfaham Tahani H
Department of Clinical Pharmacy, Faculty of Pharmacy, Assiut University, Assiut, Egypt.
Department of Cardiovascular Medicine, Faculty of Medicine, Assiut University, Assiut, Egypt.
J Clin Pharmacol. 2016 Jan;56(1):39-46. doi: 10.1002/jcph.583. Epub 2015 Sep 29.
The objective of this study was to investigate the effect of polypharmacy and high doses of amoxicillin/clavulanate on warfarin response in hospitalized patients. This was a prospective cross-sectional observational study on 120 patients from July 2013 to January 2014. Potentially interacting drugs were classified according to their tendency of increasing international normalized ratio (INR) or bleeding risk. The 87.5% of patients prescribed high-dose amoxicillin/clavulanate (10-12 g daily) compared with 28.9% of patients prescribed a normal dose (up to 3.6 g daily) had INR values ≥ 4 during the hospital stay (P ≤ .001). Increased number of potentially interacting drugs that are known to increase INR was a significant predictor of having INR values ≥ 4 (OR, 2.5; 95%CI, 1.3-4.7), and increased number of potentially interacting drugs that are known to increase bleeding risk was a significant predictor of experiencing bleeding episodes (OR, 3.1; 95%CI, 1.3-7.3). High doses of amoxicillin/clavulanate were associated with a higher risk of over-anticoagulation when combined with warfarin than were normal doses. Increased risk of having INR ≥ 4 and bleeding events was associated with increased numbers of potentially interacting drugs prescribed, indicating that polypharmacy is a problem of concern. Frequent monitoring of warfarin therapy along with patients' medications is necessary to avoid complications.
本研究的目的是调查联合用药及高剂量阿莫西林/克拉维酸对住院患者华法林反应的影响。这是一项于2013年7月至2014年1月对120例患者开展的前瞻性横断面观察性研究。根据其升高国际标准化比值(INR)或出血风险的倾向对潜在相互作用药物进行分类。与28.9%接受正常剂量(每日最高3.6 g)阿莫西林/克拉维酸治疗的患者相比,87.5%接受高剂量(每日10 - 12 g)阿莫西林/克拉维酸治疗的患者在住院期间INR值≥4(P≤0.001)。已知会升高INR的潜在相互作用药物数量增加是INR值≥4的显著预测因素(比值比[OR],2.5;95%置信区间[CI],1.3 - 4.7),已知会增加出血风险的潜在相互作用药物数量增加是发生出血事件的显著预测因素(OR,3.1;95%CI,1.3 - 7.3)。与正常剂量相比,高剂量阿莫西林/克拉维酸与华法林联用时发生抗凝过度的风险更高。INR≥4及出血事件风险增加与所开具的潜在相互作用药物数量增加相关,表明联合用药是一个值得关注的问题。为避免并发症,有必要对华法林治疗及患者的用药情况进行频繁监测。